PL421685A1 - New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease - Google Patents

New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease

Info

Publication number
PL421685A1
PL421685A1 PL421685A PL42168517A PL421685A1 PL 421685 A1 PL421685 A1 PL 421685A1 PL 421685 A PL421685 A PL 421685A PL 42168517 A PL42168517 A PL 42168517A PL 421685 A1 PL421685 A1 PL 421685A1
Authority
PL
Poland
Prior art keywords
ethylbenzene
isothiocyanate
therapy
new application
huntington disease
Prior art date
Application number
PL421685A
Other languages
Polish (pl)
Other versions
PL235541B1 (en
Inventor
Aleksandra Hać
Joanna Brokowska
Anna Herman-Antosiewicz
Original Assignee
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Gdański filed Critical Uniwersytet Gdański
Priority to PL421685A priority Critical patent/PL235541B1/en
Publication of PL421685A1 publication Critical patent/PL421685A1/en
Publication of PL235541B1 publication Critical patent/PL235541B1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem zgłoszenia jest nowe zastosowanie 2-izotiocyjanianoetylobenzenu do wytwarzania leku aktywnie hamującego powstawanie agregatów białkowych w komórce, w tym agregatów zmutowanej huntingtyny, zapobiegającego ich akumulacji, oraz aktywującemu proces ich usuwania przez komórkę. Przedmiotem zgłoszenia jest również kompozycja farmaceutyczna, która zawiera substancję aktywną 2-izotiocyjanianoetylobenzen w połączeniu z co najmniej jednym nośnikiem lub rozcieńczalnikiem farmaceutycznym, do zastosowania w leczeniu choroby Huntingtona.The subject of the application is the new use of 2-isothiocyanatoethylbenzene for the production of a drug that actively inhibits the formation of protein aggregates in the cell, including mutated huntingtin aggregates, prevents their accumulation, and activates the process of their removal by the cell. The subject of the application is also a pharmaceutical composition which contains the active substance 2-isothiocyanatoethylbenzene in combination with at least one pharmaceutical carrier or diluent for use in the treatment of Huntington's disease.

PL421685A 2017-05-23 2017-05-23 New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease PL235541B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL421685A PL235541B1 (en) 2017-05-23 2017-05-23 New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL421685A PL235541B1 (en) 2017-05-23 2017-05-23 New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease

Publications (2)

Publication Number Publication Date
PL421685A1 true PL421685A1 (en) 2018-12-03
PL235541B1 PL235541B1 (en) 2020-09-07

Family

ID=64460750

Family Applications (1)

Application Number Title Priority Date Filing Date
PL421685A PL235541B1 (en) 2017-05-23 2017-05-23 New application of 2-isothiocyanate ethylbenzene in therapy of Huntington disease

Country Status (1)

Country Link
PL (1) PL235541B1 (en)

Also Published As

Publication number Publication date
PL235541B1 (en) 2020-09-07

Similar Documents

Publication Publication Date Title
CO2019008487A2 (en) Quinazoline Compound
TR201901312T4 (en) Tetrahydronaphthalene derivatives that inhibit the Mcl-1 protein.
MX2019010907A (en) Farnesoid x receptor agonists and uses thereof.
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2017016134A (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
CR20170411A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE N- (3,5-DIMETOXIFENIL) -N- (1-METHYTILE) -N- [3- (1-METHYL-1H-PIRAZOL-4-IL-QUIN OXALIN-6-IL] ETANO-1 , 2-DIAMINE
DOP2015000304A (en) BROMODOMINIUM CRYSTAL INHIBITORS
MX2019007587A (en) Ophthalmic composition for treatment of dry eye disease.
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
DOP2019000193A (en) NEW HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
MX2018012538A (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof.
PH12018501362A1 (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
CL2015002835A1 (en) New pyridine derivatives
UY38926A (en) INHIBITION OF HUMAN INTEGRIN alfa4beta7
BR112018015367A2 (en) nanofiber oromucosal carriers for therapeutic treatment
BR112016030730A8 (en) compound
MY197464A (en) Aza-indazole compounds for use in tendon and/or ligament injuries
MX2017005522A (en) Novel treatment of cornea using laminin.
UY38352A (en) INTEGRIN INHIBITORS ALFAVBETA6
BR112017021669A2 (en) oral pharmaceutical formulations, method for treating diseases and use of said formulations